Navigation Links
Lexicon Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Date:5/31/2011

THE WOODLANDS, Texas, May 31, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 10:30 a.m. Eastern Time in New York City.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

The Jefferies Global Healthcare Conference will feature informative presentations from more than 300 leading public and private healthcare companies across the healthcare services, life sciences, medical technology, healthcare IT, and biopharmaceuticals sectors.

A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com.  An archived version of the webcast will be available for 30 days after the event on the company's website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
2. Lexicon Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
3. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
4. Lexicon to Present at Stifel Nicolaus Healthcare Conference
5. Lexicon to Present at Morgan Stanley Global Healthcare Conference
6. Lexicon to Present at Two Major Healthcare Investor Conferences
7. Lexicon Announces Pricing of Common Stock in Public Offering
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
9. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
10. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... It ... a cellular milieu; however, the broad application of this cellular target engagement concept ... sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for particular applications, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... applications were the focus of researchers, engineers, product developers, and industry suppliers gathered ... , Sponsored by SPIE, the international society for optics and photonics , ...
(Date:4/20/2017)... Netherlands (PRWEB) , ... April 20, 2017 , ... ... Technology today announced their strategic partnership to offer a full spectrum of ... authentication, a comprehensive suite of biometric products and the ground-breaking proactive cybersecurity services ...
(Date:4/20/2017)... 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ... International Liver Congress ("ILC") 2017 of the European Association for ... on the positive effects of PBI-4050 on reduction ... and metabolic syndrome. ... to Dr. Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):